TX-TRAVELWIFI
11.11.2020 13:07:13 CET | Business Wire | Press release
TravelWifi CEO Wallace Davis announced today the recent acquisition of Barcelona-based Wifivox, the leading provider of mobile Wi-Fi solutions in Spain.
Founded in 2013, Wifivox has offices in Barcelona and Madrid. The company offers rentable Wi-Fi hotspot devices that can be ordered online and then picked up or dropped off at major airports and approximately 2,000 locations throughout Spain. Wifivox has a collaborative agreement with the official Barcelona tourism board and maintains more than 830 B2B partnerships in sectors ranging from events and media production companies to travel agencies and the hospitality industry.
“Few companies in our space have such an enviable reputation for quality and service,” says TravelWifi CEO Wallace Davis. “Having Wifivox join us, further strengthens our goal to become a global leader in mobile Wi-Fi solutions.” Davis also announced that Wifivox CEO and founder Borja Ruiz will remain with the company. “I am looking forward to helping the company expand its footprint across the world,” says Ruiz. “We believe that the Spanish market offers significant opportunities for TravelWifi.”
Wifivox joins TravelWifi in offering portable Wi-Fi solutions for rent or purchase to a global market. The pocket-size devices provide unlimited data at affordable prices, allowing people to stay connected as they travel, work remotely, or even attend virtual classes for school. TravelWifi also offers SIM card solutions, as well as a growing suite of mobile business products such as routers using virtual SIM technology to provide reliable backups to primary physical internet connectivity. Wifivox is the company’s seventh acquisition, joining:
- TEP – Focused on U.S. travelers
- Trinus – Unique SIM card offerings for Latin American B2B
- Yogofi – Hospitality-centric B2C rentals and B2B2C capacity throughout Asia
- Bienvenue – Service-oriented B2B2C offerings for the travel and hospitality industries
- Travelwifi – Paris-based B2C offerings with highly visible airport and event partnerships
- Wifi Republic – A leading provider of mobile Wi-Fi solutions in Indonesia
Previously known as DHI Telecom, the Houston-based parent company rebranded itself as TravelWifi in June. “We examined how we want the world to know us,” says Davis. “The TravelWifi name encapsulates our mission and resonates with our audiences. TravelWifi offers the ability to travel simply, with innovative solutions and connection to what matters. It is the next dimension of travel. Today.”
TravelWifi uses innovative virtual SIM technology to offer a suite of products focused on Wi-Fi connectivity and managed network solutions in more than 130 countries. Customers include business and leisure travelers, organizations dependent on mobile connectivity, as well as tens of thousands of members of the U.S. military and Department of Defense overseas. Its pocket-sized flagship product – the award-winning Sapphire Wi-Fi device – uses CloudSIM technology to create a hotspot with up to 4G LTE speeds. Recent recognition includes:
- Best Military Telecommunications Providers and Most Innovative Travel Gadget by Corporate Vision Telecom Awards, 2019
- Gold in Telecommunications for Sapphire by the Golden Bridge Awards, 2019
- Named Next-Gen Wi-Fi Solution of the Year by Mobile Breakthrough Awards, 2019
View source version on businesswire.com: https://www.businesswire.com/news/home/20201111005163/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom